The epilepsy drugs market is expected to grow from US$ 7.62 billion in 2024 to around US$ 11.85 billion by 2033, with a compound annual growth rate (CAGR) of 4.57% from 2025 to 2033. This growth is mainly due to the increasing prevalence of epilepsy, adoption of advanced anti-epileptic drugs, and ongoing research into innovative treatments.